Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Use Affy Genotyping Tools for Cytogenetic Services

NEW YORK (GenomeWeb News) - Laboratory Corporation of America will use Affymetrix’s genotyping tools in a molecular cytogenetic service it will offer to US researchers, Affy said today.
 
Under the agreement, LabCorp will use Affy’s GeneChip technology in an offering that its customers can use to “correlate deletions, gains and other chromosomal rearrangements with congenital diseases such as autism, mental retardation and development delay in children,” the company said.
 
Using the GeneChip will allow LabCorp to offer researchers enhanced “resolution for the detection of the etiology of mental retardation, developmental delay, autism and other clinically significant changes,” LabCorp Executive VP, CSO, and Medical Director Myla Lai-Goldman, said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.